Datar Cancer Genetics (DCG) offers a comprehensive suite of next-generation precision-oncology diagnostics. The tests support clinicians and patients across the entire cancer care journey from healthy/asymptomatic to therapy guidance and monitoring for advanced cancers. DCG tests are for the full range of solid-organ tumours and we have 3 US FDA Breakthrough Device designations for the early detection of prostate, breast and brain cancer. Our R&D programme includes partners such as Imperial College.

We process test samples at our internationally accredited labs in the UK and provide full support throughout the process, from supplying sample collection kits to delivering results within a couple of weeks.

Our multi-cancer tests use both blood tests and tissue biopsies for:

• Early Cancer Detection: leveraging our proprietary Circulating Tumour Cell (CTC) enrichment technology for the sensitive detection of cancer at an early stage.
• Comprehensive Treatment Guidance: combining DCG’s proprietary CTC technology and multi-cancer NGS panels to bring clinically actionable recommendations – including advanced and rare cancers.
• Disease Monitoring: enabling continuous monitoring of disease status during and after treatment, allowing for timely detection of recurrence or treatment resistance.

Please visit our website for further details. For details on our peer-reviewed clinical and scientific published papers please visit our publications page here.

Alcohol Focus Scotland is the national charity working to prevent and reduce alcohol harm. We want to reduce the impact of alcohol on individuals, families, communities and Scotland as a whole, through the implementation of effective alcohol control policies and legislation. For more information, please visit: www.alcohol-focus-scotland.org.uk .

Every day in Scotland three people are diagnosed with an alcohol-related cancer, yet just over one in six (17%) people in Scotland believe there are no health risks attached to drinking alcohol and one in two don't know that alcohol causes cancer.

We are a charity based within the Beatson West of Scotland cancer centre. We provide therapeutic services to Inpatients and outpatients at the Beatson as well as 9 satellite locations in the West. Alongside this we run Specialist Health at Work services and tailored group work programmes to support those living with and effected by cancer. We also run a grants programme funding an extensive list of cancer related areas, from research, funded posts within the BWSCC, hardship grants for individuals struggling with the cost of living alongside a cancer diagnosis, to experiences for young people.

We're the UK's leading bowel cancer charity. We're determined to save lives and improve the quality of life of everyone affected by bowel cancer. Our vision is a future where nobody dies of the disease.

We provide expert information and support for everyone affected by bowel cancer. Our online forum is a place for people to talk about their experiences, share their knowledge and support each other.

We campaign for early diagnosis and access to best treatment and care across the UK. We're leading change for younger bowel cancer patients, campaigning to improve survival and quality of life for those with advanced bowel cancer and working to improve early diagnosis by ensuring people are getting the right test at the right time.

We’re Breast Cancer Now, the research and support charity. We’re dedicated to giving support for today and hope for the future, for everyone affected by breast cancer. Our vision is that by 2050, everyone diagnosed with breast cancer will live and be supported to live well.

Cancer Research UK is dedicated to saving lives through research. We support research into over 200 types of cancer, and our vision is to bring forward the day when all cancers are cured. In 2023/24, we invested over £31million in research in Scotland. 

Myeloma UK is the only UK charity to focus exclusively on the incurable blood cancer myeloma and its related conditions. It represents the 33,000 people in the UK (2,300 in Scotland) with myeloma and aims to drive better outcomes through research, treatment access, healthcare services improvement, and patient and carer information and support programmes.

Commissioned by the Scottish Government in 2021, the Scottish Cancer Network (SCN) supports the national cancer strategy through two key 'Once for Scotland' workstreams:

First, it develops, maintains, and hosts national Cancer Clinical Management Pathways, outlining the patient journey from diagnosis onward. While primarily designed for healthcare professionals, SCN is exploring ways to provide aligned information for patients.

Second, SCN hosts National Managed Cancer Networks for selected rarer cancers, including mesothelioma, sarcoma, hepatopancreatobiliary (HPB), adult neuro-oncology, and thyroid cancers.

Recently, SCN transitioned into the clinical directorate within NHS National Services Scotland (NSS), positioning itself to potentially oversee cancer services across Scotland. Although this oversight role is still in early development, SCN is actively promoting its work and engaging with stakeholders - patients, the public, and NHS professionals - to raise awareness of its current initiatives and future plans.